Abstract

A simple prospective study of the effect of lipid-lowering therapy on the assessment of quality of life was conducted using the SF-36 questionnaire for coronary heart disease in men before and after pharmacological intervention. There were no statistically significant differences in the dynamics of indicators of the SF-36 questionnaire scales both before and after treatment in patients with coronary artery disease, stable angina pectoris I—II FC with atherogenic GLP, sensitive to treatment with rosuvastatin, in comparison with a group of patients transferred to bicomponent therapy. However, when analyzing the questionnaire data of patients with coronary heart disease, taking into account the genotype, it was found that the initial values of quality of life indicators according to the SF-36 questionnaire scales in carriers of the D allele by ACEI/D polymorphism differed from those in comparison with carriers of the I allele. Thus, patients carrying the D allele showed both an initially low assessment of the quality of life and a lower dynamics of values on the scales of the SF-36 questionnaire, regardless of the type of pharmacological correction of lipid metabolism disorders. Therefore, from the point of view of the preventive approach, the connection of genetic and personal-behavioral characteristics considered as psychological risk factors for coronary heart disease is of interest.